While Big Pharma chases the next blockbuster drug, a 22-person stealth operation in the gene therapy space is quietly solving the industry's most critical bottleneck: scalable viral vector production. Virovek's BAC-to-AAV technology isn't just another lab tool—it's a potential industrial-scale solution for a market projected to hit $20 billion by 2028.

"The gene therapy revolution won't be televised—it will be manufactured. Virovek is building the factory floor."

The keyword data reveals their technical DNA: 'capillary DNA gel AAV' (720 monthly searches) and 'goi titer' (240 monthly searches) speak to a highly technical audience of process development scientists and CMC (Chemistry, Manufacturing, and Controls) specialists. These aren't casual researchers—they're the engineers building the gene therapy pipeline.

• BAC-to-AAV technology achieves 1E+17 vg yields—industrial scale from a 22-person team
• 42% direct traffic indicates strong word-of-mouth in a community that doesn't Google for solutions
• $3.4M revenue on 22 employees = ~$155K revenue per employee—highly efficient for biotech
• Traffic concentration in 'undefined' suggests either stealth mode or specialized IP-driven access